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Abstract
The identity of the Human T lymphotropic Virus type 1 (HTLV-1) receptor remained an unsolved puzzle for two
decades, until the recent demonstration that three molecules, Glucose Transporter 1, Neuropilin-1 and Heparan Sul-
fate Proteoglycans are involved in HTLV-1 binding and entry. Despite these advances, several questions remain
unanswered, including the precise role of each of these molecules during virus entry. In light of the most recent
data, we propose a model of the HTLV-1 receptor complex and discuss its potential impact on HTLV-1 infection.
Introduction
Since its identification in 1979, the Human T-Lympho-
tropic Virus type 1 (HTLV-1) has been the subject of
extensive research. Despite abundant experimental data,
several unsolved mysteries still surround HTLV-1.
Amongst those, the identity of the HTLV-1 cellular
receptor has eluded scientists for over two decades.
Since 2003, data from several independent groups have
shed light on the identity of the molecules that appear
to be directly involved in the process of HTLV-1 entry.
These include Glucose Transporter 1 (GLUT1) [1,2],
Neuropilin-1 (NRP-1) [3-5] and Heparan Sulfate Proteo-
glycans (HSPG) [6,7]. Despite these advances, our cur-
rent knowledge of their precise roles during HTLV-1
entry remains limited. In particular, little is known
about interaction between these molecules, including
whether they form a multimolecular complex similar to
that of the well-studied Human Immunodeficiency
Virus type 1 (HIV-1) receptor. In this review, we will
summarize the data pertaining to HTLV-1 entry mole-
cules, propose a hypothetical model of the HTLV-1
receptor and discuss its possible impact on the patho-
biology of HTLV-1 infection.
The HTLV-1 Receptor Enigma
HTLV-1 entry
It is widely believed that HTLV-1 enters cells in a man-
ner similar to that of other retroviruses including the
well-studied HIV-1. HTLV-1 infection of target cells is
believed to require the two virally encoded envelope gly-
coproteins (Env), the surface subunit (SU) gp46 and the
transmembrane subunit (TM) gp21, generated from the
cleavage of a polyprecursor (gp61) in the Golgi appara-
tus [8]. As has previously been shown for the SU
(gp120) and TM (gp41) of HIV-1 [9], the SU and TM of
HTLV-1 are believed to function successively during the
entry process. The gp46/SU, which does not contain a
transmembrane region, is tethered to the cell surface
through interactions with the gp21, and is involved in
direct interactions with the cell surface receptors. Like
the HIV-1 gp41, the gp21 of HTLV-1 contains a trans-
membrane region and a N-terminal hydrophobic fusion
peptide that plays a crucial role in the fusion of the viral
and cellular membrane during the final steps of HTLV-
1 entry [10,11]. Earlier work showed that both the
presence of certain mutations in the env gene and anti-
bodies directed against gp46/SU partially or totally abol-
ished HTLV-1 infection in vitro [12,13]. Infection was
also reduced by exposure of target cells to a soluble
recombinant protein containing soluble full-length SU,
indicating that it could compete with the SU on the sur-
face of the virus for the binding to yet unknown mole-
cules at the cell surface [14]. Altogether, these
experiments confirmed that the two Env glycoproteins
play crucial role during HTLV-1 entry and indicated
that, as for other retroviruses, this process depends on
the expression of cellular receptor(s) at the surface of
target cells. Interaction between gp46/SU and its cellular
receptor(s) induces a conformational change that
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fusion between the viral and cellular membranes [15].
The search for the HTLV receptor
Experimental demonstration that specific molecules
function as a virus receptor often is a challenge [16].
This is illustrated by the fact that there are a great num-
ber of viruses, including certain retroviruses, for which
no receptors have been identified. In addition, for cer-
tain viruses, it has been shown that more than one
molecule may function as entry receptors. Some viruses
use different receptors on different cell types, while
others require the presence of both molecules on a
given target cell to facilitate entry. In the case of HTLV-
1, several peculiar features of the virus and its receptor
(s) have considerably hampered research. First, free
HTLV-1 virions are poorly infectious for most cell types
and efficient infection of T cells requires a cellular con-
tact [17]. Secondly, infected lymphocytes produce a lim-
ited amount of viral particles, amongst which 1 out of
10
5 are actually infectious [18]. Lastly, the fact that
molecules capable of binding and allowing HTLV-1
entry are expressed on nearly all available established
cell lines has prevented the use of classical strategies
such as the screening of a cDNA bank in receptor-nega-
tive cells.
In vivo versus in vitro entry tropism: the paradox of the
HTLV-1 receptor
Virus tropism, the ability of a virus to replicate in parti-
cular cells, depends on interactions between viral com-
ponents and cellular factors at each step of the viral
cycle from the initial entry to the ultimate release and
transmission of virions. Here, we will focus on the cellu-
lar factors that allow HTLV-1 entry, which is deter-
mined by the distribution of the receptor molecule(s).
In vivo entry tropism
Although the main targets of HTLV-1 are CD4
+ Tc e l l s
[19], the virus has been found in other cell types in vivo
including as CD8
+ T cells [20], monocytes and B cells
[21], macrophages [22], dendritic cells (DC) [23,24] and
endothelial cells [25]. In vivo, the only known targets of
virus-induced transformation are CD4
+ CD45RO
+ mem-
ory T cells [26]. Recently, it has been hypothesized that
natural regulatory T cells (Tregs) can be infected. This
was based on the fact that HTLV-1 infected T cells and
Tregs have a strikingly close phenotype: CD25+, (which
is a direct consequence of HTLV-1 Tax synthesis [27]),
GITR+ and FoxP3+ [28,29]. If true, this could partly
explain the frequent immune dysregulation observed in
HTLV-1-infected individuals. However, studies from
other laboratories suggest that Tregs are not infected by
the virus [30,31]. This is consistent with other work
showing potent suppressive activity of HTLV-1-infected
or transformed T cells in only a portion of HTLV-1-
infected patients [32,33]. This could be due to the
impairment of FoxP3 function by the HTLV-1 Tax pro-
tein, as shown by Jacobson’s group [34]. In contrast, it
has been suggested that HTLV-1 may have an indirect
effect on Tregs since Bangham’s group recently reported
that the frequency of uninfected functional Tregs is
abnormally high in HTLV-1-infected individuals [35],
which may account as well for the immunosuppression
associated with HTLV-1 infection.
In vitro entry tropism
In striking contrast to the limited number of cell-types
in which HTLV-1 is detected in vivo, molecules capable
of supporting the initial steps in infection, binding and
entry, appear to be expressed on nearly all established
cell lines. As discussed below, this is consistent with the
fact that molecules in the receptor complex are up-regu-
lated on most transformed cells. Moreover, the HTLV-1
receptor complex is present on cell lines from nearly all
known vertebrate species [36]: most available established
cell lines are able to form multinucleated giant cells
(syncytia) when cultured with Env expressing cells, a
phenomenon that is dependent on Env/Receptor inter-
actions [37]. Further evidence that HTLV-1 receptors
are widely distributed comes from observations that
HTLV-1 Env-pseudotyped particles can infect a number
of established cell lines [38]. More recently, binding stu-
dies with soluble, full-length HTLV-1 SU (SU-Fc) has
not only confirmed the results obtained with infection
and fusion experiments but also showed that a wider
range of established cell lines expressed molecules cap-
able of specifically binding the SU protein [1]. Work
from the Brighty laboratory found that the SU-Fc pro-
tein could bind to a vast number of vertebrate cell lines
including some that were originally thought to be recep-
tor negative due to their resistance to Env-mediated cell
to cell fusion or infection [39]. This study identified one
cell line, the drosophila cell line S2, that lacked mole-
cules capable of specifically binding HTLV SU on the
cell surface. Unfortunately, these cells could not be used
to identify HTLV-1 receptors, since they have post-entry
blocks to HTLV-1 and other retroviruses.
Properties of the HTLV-1 receptor: indirect evidence
Although its ubiquitous nature considerably complicated
its identification, several properties of the HTLV-1
receptor, in particular its expression pattern on primary
cells, were characterized using indirect approaches. In
2003, two independent groups generated soluble SU
proteins by generating recombinant SU-Ig-Fc fusion
proteins containing either the full-length SU [22] or the
N-terminal portion of SU (Receptor Binding Domain,
see section 3.1) [40]. Their findings showed that the
receptor was not present at the surface of resting CD4
+
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receptor was also absent on naive T cells isolated from
cord blood but could similarly be upregulated after sti-
mulation by interleukin-7. Finally, it was reported that
the SU-Fc could inhibit a mixed lymphocyte reaction
[22]. This last property suggested that one of the mole-
cules involved in the HTLV-1 receptor was a member
of the immune synapse. Surface expression of the recep-
tor was found to be not solely dependent on T cell acti-
vation. It could also be upregulated upon exposure to
TGF-b, a potent negative regulator of the immune
response [41]. The pattern of surface expression follow-
ing exposure to TGF-b, as determined from binding of
the soluble SU, was very similar to that observed after
activation with PHA/IL-2, although with slightly slower
kinetics. It depended on the TGF-b classical signalling
pathway as it was abolished in the presence of Smad
inhibitors. TGF-b not only triggered receptor expression
at the cell surface but also increased the titer of lenti-
viral vectors pseudotyped with HTLV-1 Env in vitro,
demonstrating that molecules capable of both binding
and fusion were expressed [41]. TGF-b-treated T cells
remained in a resting state, demonstrating that T cell
activation per se was not required for receptor expres-
sion. This might constitute a strategy for the virus to
increase its infectivity [42] as HTLV-1-infected CD4
+ T
cells are known to abundantly secrete TGF-b.
Candidate receptors whose role was ruled out
Over the years, several molecules were proposed as candi-
date HTLV-1 receptors. It was proposed that the HTLV-1
receptor is encoded by chromosome 17q23.2-23.5, which
was questioned in later studies [38,43]. Most of the candi-
date receptors were identified as antigens against which
specific antibodies could inhibit Env-mediated cell fusion
[43-46]. It was later shown that some antibodies may inhi-
bit this process through non-specific protein crowding,
rather than directly competing for binding, making the
results difficult to interpret [47]. Adhesion molecules,
which strengthen and stabilize the cell-to-cell contact, can
also augment cell fusion in a non-specific manner [48].
Most importantly, none of these molecules had demon-
strated one fundamental property of the receptor, that is,
the ability to bind the HTLV-1 SU. In contrast, as it could
bind the 197-216 region of the SU, the heat shock cognate
protein HSC70 was proposed as a receptor [49]. However,
later studies showed that, while HSC70 modulates HTLV-
1-induced syncytia formation, it was dispensable for
HTLV-1 infection [50], ruling out that this molecule was
an entry receptor. The tetraspanin CD82 was also shown
to bind the HTLV-1 Env protein but was excluded as an
entry receptor on the fact that its overexpression inhibited,
rather than enhanced, syncytia formation and HTLV-1
transmission [51].
Not one but Three Receptor Molecules: GLUT1,
HSPG and NRP-1
The glucose transporter GLUT1
It was not until 2003 that work from Sitbon and Batti-
ni’s laboratory identified a candidate that matched all
the prerequisites to be a HTLV-1 receptor [2]. Further-
more, this group determined that this molecule inter-
acted with both HTLV-1 and the related virus HTLV-2,
believed to use a common entry receptor. After noticing
that overexpression of either the HTLV-1 or HTLV-2
Env in cells prevented acidification of the culture med-
ium, the authors hypothesized that the HTLV-1 receptor
might be related to the proton-dependent lactate pro-
duction. Based on their previous identification of the
receptor binding domain (RBD) of HTLV-1 or HTLV-2,
these authors further reported that the overexpression
of either the H1-RBD (first 215 residues of the HTLV-1
SU) or the H2-RBD (178 residues of the HTLV-2)
[40,52,53] altered glucose metabolism, which was consis-
tent with the frequent use of metabolite transporters as
entry receptors by retroviruses [16]. They focused on
the ubiquitous glucose transporter 1 (GLUT1), which is
upregulated in activated T cells, and found that overex-
pression of GLUT-1 in cells increased the level of bind-
ing of both the H1- or H2-RBD. In the absence of
available GLUT1-negative cell lines, they used different
approaches, in particular small interfering RNA (siRNA),
to demonstrate that GLUT1 played a role in HTLV-1
entry. Down regulation of GLUT1 by siRNA both inhib-
ited the binding of the H1- or H2-RBD and infection by
retroviral vectors pseudotyped with either the HTLV-1
or -2 Env. Both were restored after cotransfection of
GLUT1 but not GLUT3, a related glucose transporter.
They later extended their findings by that identifying a
specific residue in the HTLV-1 SU (Y114) of the H1-
RBD that appeared critical to the interaction [52], which
interacted with the 6
th extracellular loop (ECL6) of
GLUT1 [54].
Further data from other laboratories confirmed that
G L U T 1p l a y sar o l ei nH T L V - 1e n t r y .T G F - b,w h i c h
had previously been shown to upregulate molecules cap-
able of binding HTLV SU, induces GLUT1 at the sur-
face of T cells [41]. Overexpression of GLUT1 in the
bovine MDBK cell line, which is relatively resistant to
HTLV-1 infection, increases two-fold the infectious titre
of a HTLV-1 Env pseudotyped lentivirus vector [55]. A
similar result was obtained in the NIH3T3 cell line,
which is also poorly susceptible to infection by HTLV-1
pseudotyped vectors [1]. Antibodies raised against
G L U T 1E C L 1( G L U T - I g Y )b l o c kb o t hE n v - m e d i a t e d
fusion and infection. Furthermore, blocking interactions
with GLUT1 ECL1, either by replacing the GLUT1
ECL1 with that of GLUT3, or by blocking with ECL1-
derived peptides, inhibits HTLV-1-induced cell fusion,
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of GLUT1 [1]. This confirmed earlier data showing that,
although only the ECL6 was required for the binding of
the H1-RBD to GLUT1, infection by HTLV-2-pseudo-
typed viruses also required residues located in ECL1 and
ECL5 of this molecule [54]. This indicates that GLUT1
contains multiple functional determinants: those
required for interactions with the RBD portion of the
HTLV SU, located in ECL6, and others required for
interactions of the entire Env, consisting of the full-
length SU protein and the TM protein, located in ECL1
and ECL5. Thus, current data indicate that GLUT1
plays a role in HTLV-1 entry.
However, several studies suggested that the identifica-
tion of GLUT1 was not the end of the story. The astro-
cytoma/glioblastoma U87 cell line, which expresses very
low levels of GLUT-1 due to a transdominant negative
mutation in one of the alleles of GLUT1 (GLUT-1 D5),
is easily infected by HTLV-pseudotyped viruses[3,56].
Moreover, blocking interactions with GLUT1 by either
siRNA-mediated down-regulation, or by incubating with
GLUT-IgY blocking antibodies, has no effect on the
level of infection with HTLV-Env-pseudotyped virus or
HTLV Env-mediated fusion or infection in this cell line,
suggesting that molecules other than GLUT1 might be
involved [56]. An earlier study reported that overexpres-
sion of GLUT1 in a cell line (COS-7) increased cell-cell
transmission, but did not increase the level of binding of
the SU-Fc protein [57]. Similarly, more recent studies
using clones of the U87 cell line that express different
levels of GLUT1 have observed that the level of cell sur-
face GLUT1 correlates with the titer of HTLV-1 Env
pseudotyped viruses, but not with SU-Fc binding [58].
All these findings suggested that molecules other than
GLUT1 are also involved in HTLV-1 entry, especially at
the binding step.
Heparan Sulfate Proteoglycans modulate HTLV-1
attachment and entry
Molecules of the HSPG family are composed of a core
protein associated with one or more sulphated polysac-
charide side chains called heparan sulfate glycosamino-
glycans. Because of their highly negative charge, HSPG
bind through electrostatic interactions to a plethora of
proteins including growth factors and their receptors,
chemokines, cytokines and numerous proteins of the
extracellular matrix or the plasma, thereby playing a
major role in mammalian physiology [59]. Pathogens,
including many viruses, have been shown to hijack
HSPG [60]. HSPG generally enhance infection by facili-
tating the attachment of the particles on target cells
and/or allowing their clustering at the cell surface
before specific interactions between viral proteins and
their receptors that lead to fusion. For example, prior to
interaction of the HIV SU (gp120) with CD4, the initial
attachment of the virus to target cells involves specific
interactions between gp120 and cellular HSPG [61].
Rarely, a specific role of HSPG in the fusion process
has been observed, in particular with Herpes Simplex
virus [62].
The important role of HSPG in mediating attachment
and entry has also been demonstrated for HTLV-1.
Enzymatic removal of HSPG or inhibition of electro-
static interactions with dextran sulfate decreases the
binding of full length soluble SU, Env-mediated syncy-
tium formation and infection with pseudotyped viruses
[7]. These initial findings, obtained in non-lymphoid cell
lines expressing high levels of HSPG, were later con-
firmed in CD4
+ T cells in Jones and Ruscetti’s labora-
tory [6]. Although HSPG are barely detectable on
quiescent T cells [63], they are rapidly upregulated upon
activation. In CD4
+ T cells, HSPG augment both the
binding of the SU-Fc and the infectious titer of pseudo-
typed viruses [6]. The importance of HSPG was sug-
gested by studies showing that removing HSPG reduced
binding and entry of HTLV-1 virus into CD4+ T cells
and dendritic cells [4,6] and significantly reduced the
level of HTLV-1 infection.
Other recent studies suggest another role for HSPG
during cell-cell transmission of the virus. It was discov-
ered that HTLV-1 virions are stored outside the cell,
within a protective microenvironment enriched for spe-
cific components of the extracellular matrix, including
lectins and HSPGs [64]. Following contact between T
cells, these structures are rapidly transferred from
infected to uninfected cells, ultimately resulting in infec-
tion of the target cell. This suggests that HSPG could
play a broader role in HTLV-1 transmission by facilitat-
ing both the transfer of newly-formed virions from an
infected T cells and the subsequent entry into the target
T cell. The galactose-binding lectin Galactin-1, which
has been shown to increase HTLV-1-Env mediated
infection [65], might also have a similar function.
Interestingly, HSPG are important for infection with
HTLV-1 but not HTLV-2 [66], showing that these two
viruses, initially considered to share the same receptor
[67], may share some but not all molecular determinants
for entry. It has previously been reported that HTLV-1
SU has the ability to bind HSPG; this ability maps to
the C-terminal region of HTLV-1 SU, located down-
stream the RBD and the proline rich region [66]. Inter-
estingly, the Green laboratory has previously reported
that the preferential tropism of HTLV-1 and HTLV-2 to
transform CD4
+ T cells or CD8
+ T cells, respectively, is
governed by Env [68]. The difference in the requirement
of HTLV-1 and HTLV-2 two SU for HSPG might
explain the different tropisms of the two retroviruses.
Indeed, CD4
+ T cells express a high level of HSPG and
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+ T cells express a
high level of GLUT1 but very few HSPG. In this model,
the differences between HTLV-1 and HTLV-2 would be
similar to what has been described in CD4-dependent
and independent HIV-2 or SIV strains, which differ in
their requirements for the binding receptor (CD4) but
share similar fusion receptors [69].
The third player: Neuropilin-1
In 2006, the Hermine and Pique laboratories showed
that Neuropilin-1 (NRP-1) also displayed properties
expected for a HTLV-1 receptor [5]. This hypothesis
was confirmed in a recent study [3]. NRP-1 is a 130
kDa single membrane spanning glycoprotein which acts
as the co-receptor for Semaphorin 3a and VEGFA165.
NRP-1 was initially identified as a critically important
factor in embryonic neuron guidance, and later shown
to be a key player in the regulation of angiogenesis. In
addition, Romeo and Hermine’s laboratories were the
first to demonstrate that NRP-1 is also involved in the
regulation of the immune response [70]. NRP-1 is highly
conserved amongst vertebrate species but there are no
NRP-1 homologs in insects [71]. NRP-1 is mainly
expressed in T cells and DC, which are targets of
HTLV-1 in vivo. NRP-1 is highly expressed on plasma-
cytoid DC (pDC), which can be infected by cell-free
virus in vitro [72]. Endothelial cells, in which HTLV-1
proviral DNA has been detected in vivo [25], also
express NRP-1 [73]. NRP-1 is absent on resting T cells
but is rapidly upregulated following activation [72,74].
In contrast with its relatively limited expression in vivo,
NRP-1 is found in many tumor cells [73] and hence is
expressed on an extremely broad range of established
cell lines. Finally, NRP-1 plays a role in cytoskeletal
rearrangement, a phenomenon that has been shown to
be important for transmission of different retroviruses
including HTLV-1 [75].
Ghez et al. reported that NRP-1 was able to directly
interact with the HTLV-1 and -2 SU [5]. This interac-
tion appeared functionally relevant since NRP-1 overex-
pression enhanced syncytium formation and the titer of
HTLV-1 or -2 Env pseudotyped viruses whereas siRNA-
mediated NRP-1 downmodulation had the opposite
effect [5]. A strong polarization of NRP-1 and Env on
either side of the interface between an infected cell and
a target T cell was observed using confocal microscopy.
This phenomenon was also observed with GLUT1,
though GLUT1 was also found to colocalize at the
membrane junction of two uninfected T cells, thus in an
Env-independent manner. Both polarization and co-
localization of the three molecules were particularly
intense at regions where partial membrane fusion was
taking place. It was also observed that GLUT1 and
NRP-1 could form intracytoplasmic complexes in
transfected cells, an association that was greatly
enhanced in the presence of Env [5].
A new understanding of HTLV-1 tropism
The identification of three new molecules involved in
the process of HTLV-1 entry allows one to revisit the
HTLV-1 tropism paradox mentioned above. While
HSPG usage appears to distinguish HTLV-1 and HTLV-
2, their ubiquitous expression cannot explain the limited
tropism of HTLV-1 in vivo.T h i si sa l s ot h ec a s eo f
GLUT1, whose expression is ubiquitous as well. In con-
trast, the distinct pattern of NRP-1 expression in vivo
and in vitro may explain the disparity between the in
vivo and in vitro tropisms. In primary cells, NRP-1 is
mainly expressed on endothelial cells, activated CD4
+ T
cells and DC, all of which have been observed to be
infected in vivo. However, NRP-1 overexpression upon
cell transformation renders it nearly ubiquitous among
established cell lines. Moreover, the nrp-1 gene is
strongly conserved between mammalian species and has
no homolog in insects. These findings strongly favor the
notion that the in vivo HTLV-1 tropism is mainly dic-
tated by NRP-1 expression.
At Last, Several Receptors or a Receptor
Complex?
Thus, after more than 20 years, three different mole-
cules have proven to be important for HTLV-1 entry. It
seems clear that HSPG, as for nearly all other viruses, is
involved in binding but not in fusion. The properties
displayed by both GLUT1 and NRP-1, i.e. binding to the
HTLV-1 SU and modulation of infection, are consistent
with those expected for a receptor but, as mentioned
above, many questions on their exact function remain
unsolved. In particular, it is not clear whether GLUT1
and NRP-1 cooperate to promote HTLV-1 entry. We
will review very recent data that have started to clarify
the respective roles of HSPG, NRP-1 and GLUT1 in
HTLV-1 infection.
GLUT1 and NRP-1 bind distinct regions of the HTLV-1 SU
As was hypothesized previously, there is now definitive
evidence that GLUT1 and NRP-1 bind to distinct
regions of SU. Kim et al. determined that the minimal
RBD is located within the first 183 amino terminal resi-
dues of the HTLV-1 SU [52]. Mutation of the tyrosine
residue 114 completely abolished the binding of H1-
RBD, suggesting it plays a critical role. However, the
results of binding studies using RBD should be inter-
preted with caution, as they might not truly represent
what occurs with the full length SU or the SU/TM com-
plex in the native Env. Several lines of evidence suggest
that this may be the case. For example, over expression
of GLUT1 strongly increased binding of the H1-RBD
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HTLV-1 SU [57]. It is thus possible that shortening the
SU modifies its quaternary structure and mimics a con-
formational change resulting in an “active” form capable
of binding directly to GLUT1, possibly by exposing the
tyrosine residue 114 [52]. It is tempting to speculate
that the conformational change allowing the association
to GLUT1 might be dependent on the initial SU binding
to NRP-1. This would be analogous to what occurs for
HIV, where SU (gp120) binding to CD4 induces a con-
formational change that allows binding to the co recep-
tors, which facilitates fusion.
The HSPG-interacting SU region is located outside
the GLUT1 and NRP-1 binding sites, and thus should
not decrease its affinity to the other two molecules; this
interpretation is consistent with the data showing that
increasing cell surface levels of HSPG increases SU
binding to receptor-expressing cells [6,7]. Blocking the
ability of SU to interact with HSPG, either by enzymatic
removal or incubation with a peptide mimicking the
HSPG-binding domain of VEGFA165 (exon-7 peptide),
decreased the DC-mediated transfer of HTLV-1 to CD4
+ T cells by 50%. Moreover, blocking both HSPG and
NRP-1 interactions decreased HTLV-1 infection by 80%
[4,72]. Thus, HSPG are important for the efficiency of
HTLV-1 infection, likely by increasing and stabilizing
the initial SU binding to NRP-1, a phenomenon already
described for gp120 and CD4 [76].
In 2009, Lambert et al. found that the binding of the
HTLV-1 SU to NRP-1 involved two distinct types of
interaction: an indirect interaction mediated by HSPG
and a direct interaction mediated by the amino-acids
90-94 of the SU [4]. Moreover, they identified a region
of SU (aa 90-94) that is homologous in both sequence
and function to the exon 8 domain of the NRP-1 ligand
VEGFA165, [77]. This demonstrates that the SU binds to
NRP-1 using molecular mimicry of VEGFA165. Interest-
ingly, the aa 90-94 motif is conserved in the SU proteins
of HTLV-2, HTLV-3 and related Simian T-Lymphotro-
pic Viruses but not other retroviruses [4] and is the tar-
get of neutralizing antibodies [78]. Strikingly, Kim et al.
showed that mutating either aa 94 (R) or 114 (Y), which
inhibits direct interaction with NRP-1 or GLUT1
respectively, is equally efficient in preventing interfer-
ence due to overexpression of the H1-RBD in target
cells [52]. This reinforces the notion that the direct
interaction of SU with both NRP-1 and GLUT1 is
required for HTLV-1 entry.
Towards a hypothetical model of the HTLV-1 receptor
In light of these data, it is possible to draw a model for
HTLV-1 entry based on an analogy with HIV CD4/
CXCR4 or CCR5 receptor complexes, and what is
known about interactions of NRP-1 with its ligand
VEGFA165,H S P G ,a n dr e c e p t o r( F i g u r e1 ) .D u r i n gt h e
initial binding phase, the SU would interact with HSPG
via its C-terminal portion, allowing its attachment to the
cell surface (Figure 1, step 1). This would enhance the
local concentration of SU, and thus increase the prob-
ability of interactions with NRP-1. This notion is consis-
tent with observations that removal of cell surface
HSPG dramatically reduces the level of binding of the
SU or virions to CD4
+ T cells [6], the titer of pseudo-
typed virus, and the infection of CD4
+ T cells and DC.
HSPG/SU complexes would then interact with the b
domain of NRP-1, through both HSPG/NRP-1 interac-
tions and direct SU/NRP-1 binding mediated by the 90-
94 region of the SU (step 2). This binding to NRP-1
could trigger a conformational change within the SU,
exposing the region necessary for GLUT1 binding
including the critical Y114. Finally, the interaction of the
SU with GLUT1 could trigger the fusion process neces-
sary to HTLV-1 entry (step 3). In this model, NRP1,
with the help of HSPG, is the primary binding receptor,
while GLUT1 is the fusion receptor. This is consistent
with the formation of NRP-1/Env/GLUT1 complexes
and with the fact that GLUT1 over expression does not
increase the level of HTLV-1 SU binding. This model
applies to both primary CD4
+ T cells and DC [4,72].
Recent data showing that HTLV-1 entry into primary
astrocytes requires both NRP-1 and GLUT1 [3] suggest
that this view is true for these cells as well.
Whether this model is relevant for HTLV-1 entry in
other types of cells remains to be investigated. A recent
paper from Alkhatib’sg r o u ps h o w e dt h a tG L U T 1 ,b u t
not NRP-1, was involved in HTLV-1 entry into Hela
cells [3]. Moreover, the same group was the first to
show that HTLV-1 can efficiently enter into U87 cells,
in which the surface level of GLUT1 is very low [56].
Low level of GLUT1 at the cell surface could be suffi-
cient to promote fusion if the density of surface NRP1
is high, which is the case of the U87 cell line [3].
Indeed, it was shown that T cells expressing very low
levels of CCR5 but high levels of CD4 were still compe-
tent for HIV envelope-mediated membrane fusion [79].
Alternatively, NRP-1 could function on certain cell types
as both the binding and fusion receptor, as suggested for
CHO cells [3]. Finally, one cannot exclude the possibility
that, like HIV, HTLV-1 uses different fusion receptors
on different cell types and other unidentified molecules
could serve as fusion receptors for HTLV-1.
Other evidence supporting a NRP-1/GLUT1- complex
comes from reports that a small intracytoplasmic pro-
tein called GLUT1CBP or PSD-95/Dlg/ZO-1 can bind
both NRP-1 and GLUT1 via its PDZ domain [80,81].
Moreover, syndecans, the main members of the HSPG
family, also contain a PDZ-binding motif at their C-
terminus of their cytoplasmic domain [82]. Deletion of
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clude GLUT1 clustering at the plasma membrane [83].
GLUT1CBP could therefore act as a “bridge” to stabilize
the entire tripartite receptor complex. It could also pro-
vide cues for cytoskeletal polarisation, since it can
associate with several cytoskeletal proteins [80] (Figure
1, step 3). Altogether, this model not only reconciles
nearly all of the recent data obtained on the HTLV-1
receptor but also appears to explain the in vivo tropism
of the virus better than the GLUT1-only hypothesis.
Perspectives
Given its role in the immune system, the discovery of
NRP-1 as an entry molecule for HTLV-1 opens interest-
ing perspectives on viral transmission and the physiol-
ogy of HTLV-1 related diseases.
Targeting dendritic cells and disturbing the immune
response
Plasmacytoid DC (pDC), and to a lesser extent myeloid
dendritic cells (myDC), constitutively express high levels
of NRP-1, which is involved in the regulation of DC-T
cell interactions at the immune synapse [70]. Shaking
the commonly accepted idea that HTLV-1 could only be
transmitted via cell to cell contact, it was recently found
that free HTLV-1 virions could efficiently infect DC
[72]. The contact of HTLV-1-infected DC with CD4
+ T
cells upregulates NRP-1 and HSPG within an hour fol-
lowed by transmission of HTLV-1 to T cells and pro-
ductive infection. This phenomenon appears to be
dependent on both NRP-1 and HSPG expression on the
target T cells [72]. Viral transmission may occur in cis
(from virus produced from infected DCs) but also in
NRPͲ1
HSPGs
HTLVͲ1SU
GLUT1
GLUT1CBP
?
2Ͳ Bindingof
HSPG/SU l t t
1Ͳ Virusattachment
and concentration
3Ͳ StablebindingofEnvto
HSPG/NRP 1c o m p l e x e s /
4ͲRecruitmentof
GLUT1 HSPG/SUclustersto
NRP1
andconcentration
onHSPGs
HSPG/NRPͲ1complexes/
NRPͲ1dimerization
GLUT1.
Conformational
changeand
expositionofY114
Fusion
Attachment/Binding Binding/Fusion
Figure 1 Hypothetical model of the HTLV receptor complex and HTLV entry: 1- HSPG interaction with the SU allow the initial attachment
and concentration of the virions at the cell surface. 2- HSPG facilitates the recruitment of the SU to NRP-1. 3- Using molecular mimicry of
VEGFA165, the SU region 90-94 interacts with the b domain of NRP-1, an interaction that is stabilized by HSPG. 4- SU-NRP-1 interaction triggers a
conformational change within the SU, allowing exposure of the tyrosine 114 that is critical for binding to GLUT1. Interaction between GLUT1
and the SU triggers a conformational change allowing the unmasking of the TM fusion peptide (not depicted). The small adaptor protein
GLUT1CBP might form a link between NRP1 and GLUT1 and stabilize the receptor complex.
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viously shown for DC-mediated HIV infection. This
raises the question of whether DC (in particular pDC)
could constitute a reservoir for the virus. Several labora-
tories have reported detecting HTLV-1 sequences in DC
in vivo [84]. It would be interesting to determine
whether, in contrast to T cells, an active replication
cycle takes place in pDC in vivo.
Targeting DC and interfering with NRP-1 signalling
might have several other consequences on viral infec-
tion. HTLV-1 infection results in a depletion of myDC
as well as pDC and an impairment of their IFNa-produ-
cing capacity [85]. Furthermore, the number of pDC is
negatively correlated to the proviral load, suggesting a
certain degree of impairment of the antiviral response.
It is still not known whether this pDC decrease is due
to true depletion or, as in HIV infection, to their migra-
tion into lymphoid tissues. Recent in vitro data demon-
strated that cell-free HTLV-1 generates a pDC innate
immune response by an induction of costimulatory
molecules, production of massive levels of IFN-a,a n d
rapid expression of the apoptotic ligand TRAIL. The
role of NRP-1 in this process remains to be clarified.
Furthermore, HTLV-1-stimulated pDC was shown to
induce apoptosis of CD4
+ T cells expressing DR5, trans-
forming pDC into Interferon-producing Killer pDC
(IKpDC) [86]. Interaction of HTLV-1 SU binding and
NRP-1 in infected cells might by itself disturb DC-T
cells interactions, and thus impair the immune response.
This is consistent with previous reports that soluble
HTLV-1 SU has an inhibitory effect on a mixed lym-
phocyte reaction [22]. This phenomenon might be of
particular significance during primary infection when
there is an active transcription of viral products includ-
ing Env, which could thus dampen the primary antiviral
response. Alternatively, IKpDC may reduce spreading of
infection by killing infected T cells and allowing the
emergence of few infected T cell clones in the infected
host. Finally, infection of immature myDC might disturb
T cell homeostasis and lead to an increased risk of auto-
immune phenomena.
Potential effects of NRP-1 ligands
VEGFA165
Data clearly show that VEGFA165 is a potent competitor
of HTLV-1 SU binding and HTLV-1 infection of pri-
mary T cells and DC in vitro [4,72]. VEGFA165 secretion
by HTLV-1-infected cells [87] might explain the phe-
nomenon of receptor interference. By preventing the
generalised spreading of the virus, it might also explain
the peculiar course of HTLV-1 infection in which a lim-
ited number of T cell clones are infected following pri-
mary infection. Because it increases NRP-1 expression at
the surface of target cells [88], VEGFA165 might not
only have a negative effect. Sherer et al.s h o w e di na n
elegant model of MLV infection that target cells pro-
jected filopodiae towards MLV infected cells [89]. These
expansions, which the authors termed viral cytonemes,
create an intercellular bridge that allows the virus to
“slide” towards its target cell and bind to its receptor.
Endothelial cells, which have been found to be infected
in vivo [25] and coexpress NRP-1 and VEGFR2, are able
to project similar cytoplasmic expansions, or filopodiae,
towards VEGFA165 [90]. Although the relevance of this
phenomenon in other retroviral infections remains to be
studied, a similar mechanism driven by the interaction
between NRP-1 and either VEGFA165 or Env itself
might be envisaged with HTLV-1.
In ATLL it has been shown that VEGFA165 produc-
tion may participate in cell growth and angiogenesis
[91,92]. At this stage of the disease, the NRP-1/
VEGFA165 interaction may occur because the virus Env
is no longer expressed in vivo.
Semaphorin-3a
Another major NRP-1 ligand, sema3a, could also play a
role in the regulation of HTLV-1 infection. Polarization
of the cytoskeleton is a critical determinant of transmis-
sion in a number of retroviruses including HIV-1 and
HTLV-1 [75]. Although Tax has been shown to accu-
mulate at the cell-cell junction and be involved in the
microtubule reorganization [84], little is known about
the precise mechanisms responsible for this phenom-
enon. In the central nervous system, sema3a blocks F-
actin polymerization, which results in the repulsion of
the axon growth cone [93]. In the immune system,
sema3a-NRP-1 interactions inhibit the cytoskeletal
polarization following the contact between a DC and a
T cell [74]. This process may provide the negative feed-
back cues to disorganize the immune synapse, allowing
T cells to migrate from DC. In HTLV-1 infection,
s e m a 3 ac o u l dp l a yan e g a t i v er o l eb yi n h i b i t i n gt h e
cytoskeletal rearrangement that is necessary for HTLV-1
entry. Thus, interaction between the Env and NRP-1
may prevent the action of Sema3A on the activated T
cell target, thus allowing HTLV-1 infection.
Conclusion
The recent discovery that GLUT1, NRP-1 and HSPG are
involved in HTLV-1 entry sheds new light on HTLV-1
infection and the physiopathology of HTLV-1-related
diseases. The demonstration that HTLV-1 uses mole-
cules involved in the immune response and can infect
dendritic cells more efficiently than CD4
+ T cells pro-
vides fascinating perspectives for future research.
Further work is clearly needed to better define the pre-
cise role of the elements of this “ménage à trois” and its
consequence on infected individuals. A better under-
standing of the effect of HTLV-1 infection on the
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Page 8 of 11immune system could lead to the development of alter-
native strategies in the treatment of HTLV-1-related dis-
eases early in the course of the infection or even at a
later stage, as in ATLL.
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